Search Our Site

News tagged with:

"pharmaceuticals"

Restricting Pharma Reps’ Access Cuts Brand-Name Prescribing

Policies that restrict pharmaceutical sales representatives’ visits to physicians are associated with modest but significant reductions in prescriptions for detailed drugs, according to a study  published online May 2 in JAMA. Restrictive policies were also associated with a modest rise in prescribing of less costly generic medications, and hence may help rein in the rising cost of... Read More »

Read More →

Policies that restrict pharmaceutical sales representatives’ visits to physicians are associated with modest but significant reductions in prescriptions for detailed drugs, according to a study  published online May 2 in JAMA. Restrictive policies were also associated with a modest rise in prescribing of less costly generic medications, and hence may help rein in the rising cost of… Read More »

[...]

Read More

Children’s medications prove tricky for production, profitable for drug companies

Patent laws, government incentives, meant to encourage development of less-profitable drugs, enable some companies to get a leg up, set high prices. When prescribing medications, caring for children poses a particular challenge. They’re not just little adults. Their still-developing brains and bodies metabolize drugs differently, and what works for grown-ups can yield radically different —... Read More »

Read More →

Patent laws, government incentives, meant to encourage development of less-profitable drugs, enable some companies to get a leg up, set high prices. When prescribing medications, caring for children poses a particular challenge. They’re not just little adults. Their still-developing brains and bodies metabolize drugs differently, and what works for grown-ups can yield radically different —… Read More »

[...]

Read More

Allergan, true to its ‘social contract’ pledge, rolls out sub-10% price increases for 2017

Back in September, Allergan promised to limit price increases as part of a “social contract” with patients. And now it’s making good on its word. The company hiked prices on a crop of its branded meds for 2017, with the new stickers effective as of Jan. 1. But in line with its vows, it kept... Read More »

Read More →

Back in September, Allergan promised to limit price increases as part of a “social contract” with patients. And now it’s making good on its word. The company hiked prices on a crop of its branded meds for 2017, with the new stickers effective as of Jan. 1. But in line with its vows, it kept… Read More »

[...]

Read More

The bill Pharma wants to bottle up

Few pocketbook issues are as widespread or as hard to fathom as the soaring cost of prescription drugs. In the past five years, prices for the nation’s 10 top selling medications – for high cholesterol, arthritis, diabetes, depression and other common conditions – have shot up 50 percent, 100 percent and even higher. In the... Read More »

Read More →

Few pocketbook issues are as widespread or as hard to fathom as the soaring cost of prescription drugs. In the past five years, prices for the nation’s 10 top selling medications – for high cholesterol, arthritis, diabetes, depression and other common conditions – have shot up 50 percent, 100 percent and even higher. In the… Read More »

[...]

Read More

Anthem sues Express Scripts for $15 billion over drug pricing

Health insurer Anthem has sued Express Scripts Holding Co., alleging the pharmacy benefits manager is not passing along billions of dollars in savings from negotiated drug prices. Anthem is seeking $15 billion in damages and the ability to end its contract with Express Scripts. An Anthem spokeswoman said the damages reflect drug price overpayments Anthem... Read More »

Read More →

Health insurer Anthem has sued Express Scripts Holding Co., alleging the pharmacy benefits manager is not passing along billions of dollars in savings from negotiated drug prices. Anthem is seeking $15 billion in damages and the ability to end its contract with Express Scripts. An Anthem spokeswoman said the damages reflect drug price overpayments Anthem… Read More »

[...]

Read More

NIH to fund trial of pill to treat lupus owned by Norwood’s Corbus Pharmaceuticals

Testing a new pill as a treatment lupus, an autoimmune disease estimated to affect 1.5 million people in the U.S., is the aim of a mid-stage trials being announced today by Corbus Pharmaceuticals and funded wholly by the federal government. Norwood-based Corbus (Nasdaq: CRBP) said this morning that the National Institutes of Health will foot... Read More »

Read More →

Testing a new pill as a treatment lupus, an autoimmune disease estimated to affect 1.5 million people in the U.S., is the aim of a mid-stage trials being announced today by Corbus Pharmaceuticals and funded wholly by the federal government. Norwood-based Corbus (Nasdaq: CRBP) said this morning that the National Institutes of Health will foot… Read More »

[...]

Read More

Americans Don’t Like Pharma And Think They’re Getting Ripped Off

WASHINGTON — Americans use prescription drugs and they know these medicines help people, but they still don’t care much for pharmaceutical companies and think the industry is too money-hungry, according to a new survey. More than seven in 10 Americans think prescription drug prices are unreasonable, the Henry J. Kaiser Family Foundation reported Thursday. And... Read More »

Read More →

WASHINGTON — Americans use prescription drugs and they know these medicines help people, but they still don’t care much for pharmaceutical companies and think the industry is too money-hungry, according to a new survey. More than seven in 10 Americans think prescription drug prices are unreasonable, the Henry J. Kaiser Family Foundation reported Thursday. And… Read More »

[...]

Read More
Categories
Archives